Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Kisqali

Kisqali 200 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 14

HOS-136275 · Präparat HOS-097860

Frequency Patients with early breast cancer Patients with advanced or with starting dose 400 mg ribociclib metastatic breast cancer with starting dose 600 mg ribociclib Infections and infestations Very common Infections1 Infections1 Blood and lymphatic system disorders Very common Neutropenia, leukopenia Neutropenia, leukopenia, anaemia, lymphopenia Common Anaemia, thrombocytopenia, Thrombocytopenia, febrile lymphopenia neutropenia Uncommon Febrile neutropenia - Metabolism and nutrition disorders Very common - Appetite decreased Common Hypocalcaemia, hypokalaemia, Hypocalcaemia, hypokalaemia, appetite decreased hypophosphataemia Nervous system disorders Very common Headache Headache, dizziness Common Dizziness Vertigo Eye disorders Common - Lacrimation increased, dry eye Cardiac disorders Common - Syncope Respiratory, thoracic and mediastinal disorders Very common Cough Dyspnoea, cough Common Dyspnoea, interstitial lung disease Interstitial lung disease (ILD) / (ILD) / pneumonitis pneumonitis Gastrointestinal disorders Very common Nausea, diarrhoea, constipation, Nausea, diarrhoea, vomiting, abdominal pain2 constipation, abdominal pain2, stomatitis, dyspepsia Common Vomiting, stomatitis3 Dysgeusia Hepatobiliary disorders Common Hepatotoxicity4 Hepatotoxicity4 Skin and subcutaneous tissue disorders Very common Alopecia Alopecia, rash5, pruritus Common Rash5, pruritus Dry skin, erythema, vitiligo Rare - Erythema multiforme Not known - Toxic epidermal necrolysis (TEN) Musculoskeletal and connective tissue disorders Very common - Back pain General disorders and administration site conditions Very common Fatigue, asthenia, pyrexia Fatigue, peripheral oedema, pyrexia, asthenia Common Peripheral oedema, oropharyngeal pain Oropharyngeal pain, dry mouth

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.